In a video interview, Jacob Dubroff, M.D., Ph.D., discussed the potential impact of the recent CMS proposal to rein in Medicare coverage restrictions on the use of amyloid positron emission tomography (PET) for patients with Alzheimer’s disease.
While amyloid positron emission tomography (PET) was originally viewed as a diagnostic test to help detect Alzheimer’s disease, Jacob Dubroff, M.D., Ph.D., said the recently issued proposal from the Centers for Medicare and Medicaid Services (CMS) to address prior Medicare coverage restrictions for this imaging “opens the opportunity” for the use of amyloid PET to assess treatment efficacy.
In a recent interview, Dr. Dubroff said amyloid PET imaging may help physicians and patients navigate a shifting ratio of benefits and risks such as amyloid-related imaging abnormalities (ARIA) during the use of anti-amyloid therapies.
“If you already got the benefit of the drug and don’t need more treatment, it’s good to stop because you don’t want to have the risks. Risks could be more side effects, hospitalizations, and more cost. I don’t know exactly how much amyloid PET imaging will be reimbursed for but hypothetically, let’s say it’s $2,000 or $3,000. If you can prevent an admission for $20,000, that is money well spent,” noted Dr. Dubroff, the modality chief of nuclear medicine and therapy, and associate professor of radiology at the Hospital of the University of Pennsylvania.
(Editor’s note: For related content, see “CMS Proposes Lift of Coverage Restrictions on PET imaging for Alzheimer’s Disease” and “Hybrid PET/MRI Assessment with Hippocampal Radiomics May Facilitate Early Alzheimer’s Diagnosis.”)
Dr. Dubroff emphasized the amyloid PET scan represents “an elegant, well-tolerated safe test” that can be utilized for diagnosis as well as the assessment of treatment effectiveness. While noting that the CMS proposal provides hope for improved Medicare coverage of amyloid PET imaging for patients with Alzheimer’s disease, Dr. Dubroff said balancing the benefits and risks with the considerable costs of anti-amyloid therapies and imaging will be a challenging conundrum.
“If you open the floodgates and allow all the testing and all the treatment, that is going to be a lot of money,” noted Dr. Dubroff. “How do we do this in a way that makes sense where we can get the most benefit out of imaging and the drug?”
For more insights from Dr. Dubroff, watch the video below.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
Study Assesses Amyloid PET/MRI Combination in Detection of Alzheimer’s Disease
July 15th 2024Emerging research revealed that a machine learning combination of amyloid beta PET and structural MRI demonstrated an 89 percent AUC in differentiating between older healthy patients and those with Alzheimer’s disease.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
Study Shows PET/CT is Superior to SPECT/CT in Managing Patients with Primary Hyperparathyroidism
June 21st 2024F18-choline PET/CT imaging guidance for minimally invasive parathyroidectomy (MIP) procedures led to a 29 percent higher percentage of normocalcemia at one month post-op in comparison to imaging guidance with Tc99m-sestaMIBI (MIBI) SPECT/CT, according to new research.